tev-53408
Biologicalexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2024 (NCT06625177)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-15INHIBITOR
IL15 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06807463 | Phase 2 | Mar 26, 2025 | Teva |
| NCT06625177 | Phase 1 | Nov 15, 2024 | Teva |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1